PHG

PHG

USD

Koninklijke Philips N.V. NY Registry Shares

$28.020-0.180 (-0.638%)

Preço em tempo real

Healthcare
Dispositivos médicos
Países Baixos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$28.200

Máximo

$28.525

Mínimo

$27.830

Volume

1.00M

Fundamentos da empresa

Capitalização de mercado

26.9B

Setor

Dispositivos médicos

País

Netherlands

Estatísticas de negociação

Volume médio

0.74M

Bolsa de valores

NYQ

Moeda

USD

Faixa de 52 semanas

Mínimo $21.48Atual $28.020Máximo $29.29

Notícias relacionadas

GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA

Ver mais
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
BusinessWire

Philips Joins the Forever Promise Project to Honor American Veterans

Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced its support of the Forever Promise Project, an initiative of the Monuments Men and Women Foundation that connects American

Ver mais
Philips Joins the Forever Promise Project to Honor American Veterans
GlobeNewswire

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA

October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport

Ver mais
Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA
GlobeNewswire

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major

Ver mais
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.